Core Insights - Medicus Pharma Ltd. has submitted an FDA Commissioner's National Priority Voucher (CNPV) application for its product Skinject (SKNJCT-003), which utilizes a Doxorubicin Microneedle Array (D-MNA) to treat basal cell carcinoma (BCC) non-invasively [1][4][5] - The CNPV program aims to expedite the review process for drugs that align with U.S. national health priorities, potentially reducing review times from 10-12 months to 1-2 months [2][3] - Skinject addresses a significant public health need, offering a non-surgical alternative for BCC treatment, which affects over five million new cases annually in the U.S. [6][7] Company Developments - The company is conducting a Phase 2 clinical study (SKNJCT-003) across nine clinical sites in the U.S., with a focus on evaluating lesion clearance rates and patient tolerability [10][11] - An interim analysis of SKNJCT-003 showed over 60% clinical clearance, with the study expanding to include 90 participants [11][12] - Medicus has received regulatory approvals in the U.K. to expand its Phase 2 study, confirming compliance with local clinical standards [15][32] Product and Technology - Skinject is a single-use, dissolvable microneedle array that delivers a localized therapeutic agent directly into BCC lesions, providing a cost-effective and minimally invasive treatment option [8][9] - The product specifically targets patients with Gorlin syndrome, a rare genetic disorder that leads to multiple BCCs, addressing their unmet medical needs [9][21] Strategic Collaborations - Medicus has entered a collaboration with the Gorlin Syndrome Alliance to facilitate expanded access to Skinject for patients with recurrent or inoperable BCCs [21][22] - The company also announced a non-binding memorandum of understanding with Helix Nanotechnologies to explore co-development of mRNA-based vaccines [18][25] Market Context - The CNPV program is part of a broader initiative by the FDA to enhance drug development for pressing health issues in the U.S., including cancer care access and affordability [2][3][4] - The introduction of Skinject is positioned to reduce healthcare costs and surgical dependence for BCC treatment, aligning with national health priorities [5][17]

Core Viewpoint - Boise Cascade Company (NYSE:BCC) is facing challenges due to its connection to the housing market, which is currently underperforming. The company is considered too leveraged to a specific segment of the market, making it less favorable compared to larger home improvement retailers, especially in the context of potential Federal Reserve rate cuts [1]. Group 1: Company Overview - Boise Cascade Company manufactures engineered wood products and plywood, and distributes building materials such as lumber, siding, roofing, and millwork [2]. - Third Avenue Management has initiated new positions in Boise Cascade Company, indicating interest in the building materials distributor and manufacturer [2].

Core Insights - The article focuses on Boise Cascade (BCC), a leading manufacturer of plywood and engineered wood products in North America, highlighting its significance in the forest industry [1]. Company Overview - Boise Cascade is recognized as one of the largest manufacturers in its sector, specifically in plywood and engineered wood products [1]. Personal Journey - The author shares a personal narrative about their journey in the investment banking industry, emphasizing the challenges and growth experienced over a decade [1]. Lifestyle and Environment - The author describes a lifestyle change, living in a yurt in the boreal forest, which reflects a deep connection with nature and a simpler way of life [1].

Group 1: Doximity, Inc. (NYSE:DOCS) - Doximity reported quarterly earnings of 45 cents per share, exceeding the analyst consensus estimate of 38 cents per share [1] - The company achieved quarterly sales of $168.525 million, surpassing the analyst consensus estimate of $157.614 million [1] - Jim Cramer advised waiting before purchasing Doximity shares, stating they are "still too expensive" [1] Group 2: IREN Limited (NASDAQ:IREN) - IREN reported quarterly earnings of $1.08 per share, significantly beating the consensus estimate of 14 cents [2] - The company's quarterly revenue was $240.3 million, exceeding the Street estimate of $235.5 million and up from $49.57 million in the same period last year [2] - Jim Cramer recommended selling half of IREN stock [2] Group 3: Boise Cascade Company (NYSE:BCC) - Boise Cascade reported quarterly earnings of 58 cents per share, missing the analyst consensus estimate of 76 cents per share [3] - The company reported quarterly sales of $1.668 billion, which beat the analyst consensus estimate of $1.623 billion [3] - Jim Cramer expressed concerns about the housing sector and suggested that Boise Cascade is too leveraged to a specific part of the market [3] Group 4: Price Action - Doximity shares fell 3.3% to settle at $50.96 [5] - IREN shares declined 2.9% to close at $55.70 [5] - Boise Cascade shares rose 0.9% to settle at $70.28 [5]

Core Viewpoint - Medicus Pharma Ltd. has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) for Doxorubicin Microneedle Array (D-MNA) aimed at non-invasive treatment of basal cell carcinoma (BCC) of the skin [1]. Group 1 - The expansion of the clinical study into the UK is intended to enhance global patient recruitment and clinical dataset for a pivotal study program [1]. - The focus of the study is on evaluating a novel therapeutic asset, D-MNA, which represents a potentially disruptive approach in the treatment of BCC [1].

Core Insights - Boise Cascade's third quarter results showed a positive market reaction despite lower earnings, with revenue exceeding Wall Street expectations due to steady demand in general line product categories and expanded next-day delivery services [1][3] - CEO Nate Jorgensen noted that customer reliance on Boise Cascade's distribution network helped mitigate volume and pricing challenges in the wood products segment [1] - Ongoing investments in capacity and strategic partnerships contributed to stable business operations during a period of industry softness [1] Financial Performance - Revenue for Q3 was $1.67 billion, surpassing analyst estimates of $1.62 billion, representing a 2.7% year-on-year decline but a 3.1% beat [6] - Adjusted EPS was $0.58, missing analyst expectations of $0.69 by 15.7% [6] - Adjusted EBITDA was $74.38 million, in line with analyst estimates of $74.47 million, with a margin of 4.5% [6] - Operating margin decreased to 1.9%, down from 6.8% in the same quarter last year [6] - Market capitalization stood at $2.62 billion [6] Analyst Insights - Analysts raised questions regarding share gains in general line products, with growth attributed to investments in capacity and partnerships [6] - Constraints on BMD segment margins were discussed, with management citing product mix improvements and operational flexibility as key factors [6] - Price stabilization in EWP and channel inventory levels were addressed, indicating reduced competitive pressure and balanced inventories could support price recovery [6] - The impact of new supplier partnerships, particularly with James Hardie, was highlighted as a driver of new revenue in untapped markets [6] - Recent declines in distribution EBITDA margins were attributed to seasonal sales patterns rather than structural shifts, with confidence expressed in a return to normalized margins as volumes recover [6]

Core Insights - Third Avenue Management's "Third Avenue Small-Cap Value Fund" reported a return of 7.18% in Q3 2025, underperforming the MSCI USA Small-Cap Value Index at 8.97% and the Russell 2000 Value Index at 12.60% [1] - The fund's performance was positively influenced by contributions from a diverse range of businesses [1] Company Highlights - Boise Cascade Company (NYSE:BCC) was highlighted as a key stock in the fund's Q3 2025 investor letter, involved in the distribution and manufacturing of building materials and engineered wood products [2][3] - Over the last month, Boise Cascade Company (NYSE:BCC) experienced a return of -3.40%, and its stock price decreased by 49.32% over the past 52 weeks, closing at $71.38 on November 5, 2025, with a market capitalization of $2.644 billion [2]

Financial Data and Key Metrics Changes - Consolidated third-quarter sales were $1.7 billion, down 3% from the third quarter of 2024 [3] - Net income was $21.8 million, or $0.58 per share, compared to $91 million, or $2.33 per share, in the year-ago quarter [3] - Gross margin for the third quarter was 15.1%, a 60 basis point year-over-year decline [8] - BMD's EBITDA margin was 4.5% for the quarter, down from 5.6% in the year-ago quarter [8] Business Line Data and Key Metrics Changes - Wood product sales in the third quarter were $396.4 million, down 13% compared to the third quarter of 2024 [5] - BMD sales in the quarter were $1.6 billion, down 1% from the third quarter of 2024 [5] - I-Joist and LVL volumes were down 10% and 7% respectively compared to the year-ago quarter [6] - Plywood sales volume was $387 million compared to $391 million in the third quarter of 2024 [7] Market Data and Key Metrics Changes - U.S. housing starts increased 2% year-over-year, while single-family housing starts decreased 3% [3] - BMD's year-over-year third-quarter sales decline of 1% was driven by a 1% decrease in price, with sales volumes flat [8] - BMD's daily sales pace in October was approximately 5% below the third-quarter sales pace [15] Company Strategy and Development Direction - The company remains focused on a two-step distribution model and enhancing its market-leading EWP and plywood franchises [4] - Capital expenditures for the nine months ended September 2025 were $187 million, with a commitment to a capital spending range of $230 million to $250 million for 2025 [10][11] - The company is expanding its market-leading national distribution presence, including the opening of a new distribution center in Texas [11] Management's Comments on Operating Environment and Future Outlook - Management expects demand weakness, trade policy uncertainties, and seasonal factors to influence financial results in the fourth quarter [13] - Early industry projections for 2026 are consistent with 2025 housing starts levels, with gradual improvement expected later in the year [17] - The company anticipates that prices for EWP have bottomed and expects to move prices higher as 2026 progresses [18] Other Important Information - The company paid $27 million in regular dividends in the nine months ended September 30, 2025, and has authorized up to $300 million for share repurchases [12] - The company is focused on maintaining a balanced capital deployment strategy, investing in existing assets while pursuing growth opportunities [13] Q&A Session Summary Question: Can you talk about share gains in the general line part of the business? - Management noted that demand held up well in general line product categories due to significant investments in capacity and partnerships with suppliers [21][22] Question: Can you discuss competitive dynamics in EWP and pricing confidence? - Management indicated that prices have stabilized and they expect to see improvements in pricing as demand recovers [25][28] Question: What are the constraints for generating higher margins in BMD? - Management expressed confidence in maintaining gross margins above 15% and highlighted the importance of enriching the product mix [32][34] Question: How is the company planning to balance M&A with share repurchases? - Management stated that their priorities remain investing in existing assets and pursuing organic growth, with share repurchases being active in the absence of meaningful M&A [72]

Financial Data and Key Metrics Changes - Consolidated third-quarter sales were $1.7 billion, down 3% from the third quarter of 2024 [3] - Net income was $21.8 million, or $0.58 per share, compared to $91 million, or $2.33 per share, in the year-ago quarter [3] - Gross margin for the third quarter was 15.1%, a 60 basis point year-over-year decline [8] - BMD's EBITDA margin was 4.5% for the quarter, down from 5.6% in the year-ago quarter [8] Business Line Data and Key Metrics Changes - Wood product sales in the third quarter were $396.4 million, down 13% compared to the third quarter of 2024 [5] - BMD sales in the quarter were $1.6 billion, down 1% from the third quarter of 2024 [5] - I-joist and LVL volumes were down 10% and 7% respectively compared to the year-ago quarter [6] - Plywood sales volume was $387 million compared to $391 million in the third quarter of 2024 [6] Market Data and Key Metrics Changes - U.S. housing starts increased 2% year-over-year, while single-family housing starts decreased 3% [3] - BMD's year-over-year third-quarter sales decline of 1% was driven by a 1% decrease in price, with sales volumes flat [7] - BMD's daily sales pace in October was approximately 5% below the third-quarter sales pace [15] Company Strategy and Development Direction - The company remains focused on a two-step distribution model and enhancing its market-leading EWP and plywood franchises [4] - Capital expenditures for the nine months ended September 2025 were $187 million, with a capital spending range for 2025 at $230-$250 million [10][12] - The company is committed to a balanced deployment of capital, investing in existing assets, pursuing organic and M&A growth opportunities, and returning capital to shareholders [13] Management's Comments on Operating Environment and Future Outlook - Management expects demand weakness, trade policy uncertainties, and seasonal factors to influence financial results in the fourth quarter [13] - Early industry projections for 2026 are consistent with 2025 housing starts levels, with gradual improvement expected later in the year [17] - The company anticipates that EWP prices have bottomed and expects to move prices higher as 2026 progresses [18] Other Important Information - The company paid $27 million in regular dividends in the nine months ended September 30, 2025, and repurchased approximately $120 million of common stock [12] - The board of directors authorized up to $300 million of common stock repurchases under a new share repurchase program [12] Q&A Session Summary Question: Can you talk about the share gains in the general line part of the business? - Management noted that demand held up well in general line product categories due to significant investments in added capacity and a broader mix of products [21][22] Question: Can you discuss the competitive dynamics in EWP and pricing confidence? - Management indicated that prices have stabilized and they expect to see improvements in pricing as the demand environment improves [25][26] Question: What are the constraints for generating higher margins in BMD? - Management expressed confidence in maintaining gross margins above 15% and highlighted the importance of enriching the product mix [33][34] Question: How is the company planning to balance M&A with share repurchases? - Management stated that the priority is to invest in existing assets and pursue organic growth, while also being active with share repurchases if no meaningful M&A opportunities arise [77]

Financial Data and Key Metrics Changes - Consolidated third-quarter sales were $1.7 billion, down 3% from Q3 2024 [3] - Net income was $21.8 million, or $0.58 per share, compared to $91 million, or $2.33 per share, in the year-ago quarter [3] - Wood product sales were $396.4 million, down 13% compared to Q3 2024, with segment EBITDA of $14.5 million compared to $77.4 million in the prior year [5] - BMD sales were $1.6 billion, down 1% from Q3 2024, with segment EBITDA of $69.8 million compared to $87.7 million in the prior year [5][6] - Gross margin was 15.1%, a 60 basis point year-over-year decline [9] Business Line Data and Key Metrics Changes - Wood products experienced lower sales volumes and competitive pricing pressure, particularly in EWP and plywood [3][4] - I-joist and LVL volumes were down 10% and 7% respectively compared to the year-ago quarter [6] - BMD's commodity sales decreased 3%, while general line product sales increased 6% [8] - EWP volumes were down 15% sequentially, with pricing pressures leading to declines of 6% and 5% for I-joist and LVL respectively [7][9] Market Data and Key Metrics Changes - U.S. housing starts data for September 2025 was not released, but total U.S. housing starts increased 2% when comparing July and August 2025 to the same periods in 2024 [3] - Single-family housing starts decreased 3% [3] - BMD's daily sales pace in October was approximately 5% below the Q3 sales pace [16] Company Strategy and Development Direction - The company remains focused on executing strategic priorities, including a two-step distribution model and enhancing product offerings [4][10] - Capital expenditures for the first nine months of 2025 were $187 million, with a commitment to a capital spending range of $230-$250 million for the year [11][12] - The company anticipates a cautious market in the first half of 2026, with gradual improvement expected later in the year [18][20] Management's Comments on Operating Environment and Future Outlook - Management noted demand weakness, trade policy uncertainties, and seasonal factors will influence financial results [13][15] - EWP prices have stabilized, and management expects low single-digit sequential declines due to market adjustments [15] - The company is confident in long-term demand drivers for residential construction, including housing supply shortages and demographic trends [19][20] Other Important Information - The company paid $27 million in regular dividends in the nine months ended September 30, 2025, and repurchased approximately $120 million of common stock [12] - A new share repurchase program of up to $300 million was authorized [12] Q&A Session Summary Question: Can you talk about share gains in the general line part of the business? - Management highlighted strong demand in general line product categories and significant investments in capacity to support growth [22][23] Question: What are the competitive dynamics in EWP? - Management noted price stabilization and a focus on maintaining cycle times for builders as key factors influencing EWP pricing [25][28] Question: What are the constraints for generating higher margins in BMD? - Management expressed confidence in maintaining gross margins above 15% and emphasized the importance of enriching the product mix [33][34] Question: How is the company planning to balance M&A with share repurchases? - Management stated that capital allocation priorities remain focused on investing in existing assets and pursuing organic growth, with share repurchases expected to continue in the absence of meaningful M&A [73]